Archives for 

U.S. Supreme Court Decisions

Amgen v. Sandoz: Federal Circuit Vacates Opinion and Mandate, Reinstates Appeal, Orders Further Briefing on Remanded Issues

Amgen v. Sandoz (filgrastim)  •  Approved Biosimilar Products  •  Biologics Litigation  •  Biosimilar News  •  BPCIA and Related U.S. Statutes  •  U.S. Biosimilar Litigation News  •  U.S. Federal Circuit Decisions  •  U.S. Supreme Court Decisions
As we previously reported, following the Supreme Court’s decision in Sandoz v. Amgen, Sandoz requested a remand to the District Court to answer the two questions that the […]

View More

MYLAN, APOTEX, COHERUS, AND ADELLO FILE AMICUS BRIEFS IN SANDOZ V. AMGEN

Amgen v. Sandoz (filgrastim)  •  Patent Dance  •  U.S. Biosimilar Litigation News  •  U.S. Supreme Court Decisions
As we covered in previous posts, the Supreme Court will hear arguments regarding the Federal Circuit’s interpretation of the BPCIA’s notice of commercial marketing requirement and patent dance provisions in April 2017.  Several amicus briefs in support […]

View More